Weekly Research Analysts’ Ratings Changes for Qiagen (QGEN)

Qiagen (NYSE: QGEN) recently received a number of ratings updates from brokerages and research firms:

• 2/9/2026 – Qiagen was given a new $52.00 price target on by analysts at UBS Group AG.
• 2/6/2026 – Qiagen was given a new $53.00 price target on by analysts at Robert W. Baird.
• 2/6/2026 – Qiagen had its “hold” rating reaffirmed by analysts at TD Cowen.
• 2/6/2026 – Qiagen was given a new $50.00 price target on by analysts at Stifel Nicolaus. They now have a “hold” rating on the stock.
• 2/6/2026 – Qiagen was given a new $58.00 price target on by analysts at Barclays PLC. They now have an “overweight” rating on the stock.
• 2/6/2026 – Qiagen had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $60.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – Qiagen had its price target lowered by analysts at Citigroup Inc. from $55.40 to $55.00. They now have a “neutral” rating on the stock.
• 2/5/2026 – Qiagen had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $59.00 price target on the stock.
• 1/22/2026 – Qiagen was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating. They now have a $54.00 price target on the stock, up previously from $52.00.
• 1/21/2026 – Qiagen had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 1/10/2026 – Qiagen was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/29/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Qiagen had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/21/2025 – Qiagen was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.